Syndevrx, Inc. reported raising $16.3M in an amended private placement filing on March 20, 2017
Mar 22, 2017
Syndevrx, Inc. develops treatments for metabolic-related diseases. Its product includes SDX-7320, a polymer conjugate of fumagillol that releases a pharmacologically active small molecule fumagillol derivative in vivo. The company was founded by James M. Shanahan and Bradley J. Carver and is headquartered in Cambridge, MA.
In The News
Biotech, science, medical coalition launches Metabo-oncology.com to help solve deadly cancer-obesity crisis
Mar 26, 2019 - PR Newswire
Mar 22, 2019 - RelSci